Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma-Reference-Cited by-同舟云学术

Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma

Published:2004-09 Issue:2 Volume:5 Page:98-101
ISSN:1526-9655
Container-title:Clinical Lymphoma
language:en
Short-container-title:Clinical Lymphoma

Author:

Gordon Leo I.,Witzig Thomas,Molina Arturo,Czuczman Myron,Emmanouilides Christos,Joyce Robin,Vo Katie,Theuer Charles,Pohlman Brad,Bartlett Nancy,Wiseman Greg,Darif Mohamed,White Christine

Publisher

Elsevier BV

Subject

Cancer Research

Reference11 articles.

1. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma;Knox;Clin Cancer Res,1996

2. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma;Witzig;J Clin Oncol,1999

3. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002

4. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non- Hodgkin's lymphoma and mild thrombocytopenia: A Phase II multicenter trial;Wiseman;Blood,2002

5. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD20 antibody treatment for B-cell malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma;Future Oncology;2023-10

3. Theranostics in Hematooncology;Journal of Nuclear Medicine;2023-06-08

4. Follikuläres Lymphom;Indolente Lymphome;2023

5. Treatment of indolent lymphoma;Blood Research;2022-04-30